Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Pacira Pharmaceuticals, Inc. (PCRX) opened at $41.50 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. The stock has a market cap of $1,713.07, a price-to-earnings ratio of -31.68 and a beta of 2.20. Pacira Pharmaceuticals, Inc. has a fifty-two week low of $29.81 and a fifty-two week high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.15. The firm had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.20 EPS. sell-side analysts anticipate that Pacira Pharmaceuticals, Inc. will post -0.85 earnings per share for the current fiscal year.
Several analysts recently issued reports on PCRX shares. Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Bank of America reduced their price target on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 4th. Janney Montgomery Scott downgraded shares of Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 price target for the company. in a research report on Thursday, October 26th. Royal Bank of Canada reissued a “buy” rating and issued a $54.00 price target on shares of Pacira Pharmaceuticals in a research report on Friday, October 13th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $55.00 price target on shares of Pacira Pharmaceuticals in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $49.00.
Institutional investors and hedge funds have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. bought a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter worth $114,000. Cubist Systematic Strategies LLC raised its stake in shares of Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after purchasing an additional 1,752 shares during the period. QS Investors LLC bought a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter worth $157,000. Ameritas Investment Partners Inc. raised its stake in shares of Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after purchasing an additional 302 shares during the period. Finally, Spectrum Management Group Inc. bought a new stake in shares of Pacira Pharmaceuticals during the 3rd quarter worth $166,000.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Pacira Pharmaceuticals, Inc. (PCRX) CEO Sells 28,885 Shares of Stock” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thestockobserver.com/2018/01/14/insider-selling-pacira-pharmaceuticals-inc-pcrx-ceo-sells-28885-shares-of-stock.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.